ライフサイエンスコーパス: FPG

1 FPG 5.1 mmol/L was associated with a crude reduction in

2 FPG change values +/- SE in the third versus first terti

3 FPG concentration and beta-cell function was measured wi

4 FPG concentrations at 28 gestational weeks (IQR: 22-32 w

5 FPG was measured at baseline and again at 2 y; glucose c

6 bA1c (MD, -0.20%; 95% CI, -0.27% to -0.13%), FPG (MD, -0.34 mmol/L; 95% CI, -0.56 to -0.12 mmol/L), a

7 baseline diabetes, those missing the first 2 FPG values, and those missing 6 or more FPG values.

8 FPG <70 mg/dL: HR, 3.49 [95% CI, 2.19-5.57]; FPG 120-125 mg/dL: HR, 12.47 [10.84-14.34]).

9 of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher among non-Hispa

10 vel of 200 mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition).

11 justed prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and prediabet

12 theless, 42% of subjects developing abnormal FPG did not develop abnormal 2hPG, and vice versa.

13 y these criteria, 43% progressed to abnormal FPG and 43% to abnormal 2hPG by 10 years of follow-up; a

14 By 10 years, 14% had progressed to abnormal FPG and 48% to abnormal 2hPG.

15 n subsidiary analyses, we defined "abnormal" FPG as > or =5.55 mmol/l and "diabetic" FPG as > or =6.1

16 ea, 8%, 42%, and 24%, respectively, achieved FPG levels of less than 7.8 mmol/L (140 mg/dL) and 9%, 2

17 s a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 100 mg/dL to 125 mg/dL, or a 2-hour PG leve

18 o 59 years with a BMI of 18.5 to 24.9 and an FPG level of 95 to 99 mg/dL had an estimated 10-year dia

19 Diabetes was defined as an FPG level greater than 125 mg/dL.

20 MD = 0.65; 95% CI 0.43 to 0.88; P <0.05) and FPG (MD = 9.04; 95% CI 2.17 to 15.9; P <0.05), but no si

21 6 mg/dL, and normal glucose as A1C <5.7% and FPG <100 mg/dL.

22 st important determinants of IA were age and FPG (R(2) = 0.519, P < 0.0001), and different FPG levels

23 amyloid severity was generated with age and FPG as required variables.

24 y 1.7 to 11.6 mm Hg per 10 years of age, and FPG increased by 0.8 to 20.4 mg/dL per 10 years of age i

25 her in 2050 under the improved adult BMI and FPG and improved smoking scenarios compared with the ref

26 orecasted period with improved adult BMI and FPG, 2.1 million (1.3-2.9) fewer deaths with improved ex

27 metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healt

28 The discrepancy between chromatographic and FPG-based approaches may reflect overestimation by HPLC

29 se more steeply in high-income countries and FPG in the Oceania countries, the Middle East, and the U

30 5,687 women with pre-pregnancy diabetes and FPG measurements within one year before conception.

31 -0.86%) for the 120-mg twice daily group and FPG reductions up to a least squares mean difference vs

32 alysis determined effectiveness of HbA1c and FPG to discriminate between groups.

33 Levels of HbA1c and FPG were similar between the evolocumab and placebo grou

34 For all danuglipron doses, HbA1c and FPG were statistically significantly reduced at week 16

35 ata between ages 30 and 64 years for SBP and FPG, and between 30 and 54 years for TC.

36 f age-SBP relationship in older ages; TC and FPG age associations reversed in older ages, leading to

37 measured at baseline then every 24 weeks and FPG was measured at baseline, week 12, week 24, and ever

38 AGR was defined as FPG >/=6.1 mmol L(-)(1) (World Health Organization (WHO)

39 Diabetes was defined as FPG >6.9 mmol L(-)(1), or being on diabetes treatment.

40 cially cardiac and skeletal malformations at FPG levels >= 126 mg/dL [>= 7.0 mmol/L].

41 tients randomized to metformin, 18% attained FPG levels of less than 7.8 mmol/L (140 mg/dL) and 13% a

42 The exposure was baseline FPG level, with covariates including the following measu

43 M2.5 air quality is associated with a better FPG level and a decreased risk of type 2 diabetes develo

44 re was a positive linear association between FPG levels and spontaneous abortion, PTB, macrosomia, SG

45 Relations between FPG and offspring growth and obesity were assessed by li

46 repregnancy BMI and intention to breastfeed, FPG 5.1 mmol/L predicted earlier termination of any brea

47 Glycaemia was assessed by FPG in Thailand and by HbA1c in the UK.

48 d FPG or 2hPG, 22% progressed to diabetes by FPG whereas 17% progressed by 2hPG at 10 years.

49 years, 8% of these progressed to diabetes by FPG whereas 27% progressed by 2hPG.

50 ariables: age at onset, waist circumference, FPG, and fasting insulin.

51 according to fasting glucose concentration (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting g

52 istory of diabetes, and baseline covariates (FPG, BMI, education, smoking, and physical activity).

53 merican Diabetes Association (ADA) criteria (FPG >=5.5 mmol/L [>=100 mg/dL]); IFG based on WHO criter

54 L [>=100 mg/dL]); IFG based on WHO criteria (FPG >=6.1 mmol/L [>=110 mg/dL]); HbA(1c) based on ADA cr

55 ifications: (1) normal by the new criterion (FPG concentration <6.1 mmol/L [110 mg/dL]); (2) impaired

56 paired fasting glucose by the new criterion (FPG concentration of 6.1-6.9 mmol/L [110-125 mg/dL]); (3

57 ing Cox proportional hazards models, high CV-FPG and low 1,5-AG were independently associated with mi

58 Only CV-FPG was a significant risk factor for macroalbuminuria.

59 However, only the CV-FPG association remained after additional adjustment for

60 plasma glucose coefficient of variation (CV-FPG) was determined from 4 months postrandomization unti

61 he largest decrease in PM2.5 had a decreased FPG level (B = -0.39, 95% confidence interval: -0.47, -0

62 FG, FPG 110-125 mg/dl), and type 2 diabetes (FPG >126 mg/dl).

63 -11.0 mmol/l), and from IFG-IGT to diabetes (FPG > or =7.0 mmol/l or 2hPG > or =11.1 mmol/l).

64 ediabetic (FPG 5.6-6.9 mmol/L), or diabetic (FPG >/=7.0 mmol/L).

65 mal" FPG as > or =5.55 mmol/l and "diabetic" FPG as > or =6.1 mmol/l, making the baseline prevalence

66 PG (R(2) = 0.519, P < 0.0001), and different FPG levels were sensitive and specific to predict IA sev

67 and no self-reported history of DM; and DM: FPG >= 7.0 mmol/L or self-reported history of DM).

68 acteristics of simple models of dysglycemia (FPG>/=100 mg/dL) identification were evaluated and optim

69 FI strengthened these associations.Elevated FPG before treatment indicates success with dietary weig

70 035 participants, 5.2% and 9.5% had elevated FPG and 2hPG, respectively, consistent with a diagnosis

71 stfeeding duration among women with elevated FPG.

72 Two of the enzymes, FPG and NEIL1 known to cleave normal abasic sites (1) by

73 [(18)F]FPG conjugation with arginine residues is highly selecti

74 [(18)F]FPG constitutes a generic tool for (18)F-labeling of var

75 Thus, [(18)F]FPG is an arginine-selective bioconjugation reagent that

76 [(18)F]FPG protein conjugates are able to preserve the binding

77 [(18)F]FPG was radiosynthesized by a one-pot, two-step procedur

78 group, 4-[(18)F]fluorophenylglyoxal ([(18)F]FPG).

79 The [(18)F]FPG-HSA conjugate has prolonged blood retention, which c

80 ng glucose both between and within families (FPG 4.1-18.5 mmol/l, IQ range 5.45-10.4), with a marked

81 iteria for diabetes on or before their first FPG measurement were excluded.

82 3.0-66.9) for HbA(1c), 74.6% (72.7-76.4) for FPG, and 77.1% (75.4-78.8) for 2 h plasma glucose, where

83 tantially across populations, especially for FPG and TC.

84 The nontransmitted haplotype score for FPG was strongly associated with birth weight (p = 4.7 x

85 In diabetic patients diagnosed by the former FPG criterion, HbA1c levels were normal in 18.6% (16.7%)

86 selected for having attributable burden from FPG in GBD).

87 However, gestational FPG and prepregnancy obesity status interacted significa

88 e mothers, each unit increase in gestational FPG was associated with decreased offspring weight (B: -

89 e mothers, each unit increase in gestational FPG was associated with increased offspring weight (B: 0

90 1C (A1C) >/=6.5%, or fasting plasma glucose (FPG) >/=126 mg/dL, prediabetes as A1C 5.7%-<6.5% or FPG

91 et DM was defined as fasting plasma glucose (FPG) >= 7.0 mmol/L, documented use of glucose-lowering m

92 f diabetes and had a fasting plasma glucose (FPG) <126 mg/dl at baseline.

93 rity correlated with fasting plasma glucose (FPG) (r = 0.662, P < 0.001) and HbA1c (r = 0.726, P < 0.

94 moglobin A1c (HbA1c)/fasting plasma glucose (FPG) alone fail to diagnose or miscategorize up to 40% o

95 s the association of fasting plasma glucose (FPG) and 2-h postglucose challenge (2hPG) measured at 26

96 ted higher levels of fasting plasma glucose (FPG) and blood hemoglobin A1c (HbA1c) than individuals o

97 ncertainties in mean fasting plasma glucose (FPG) and diabetes prevalence for adults aged 25 years an

98 ed concentrations of fasting plasma glucose (FPG) and fasting insulin (FI) as prognostic markers for

99 subjects and assayed fasting plasma glucose (FPG) and insulin sensitivities.

100 moglobin (HbA1c) and fasting plasma glucose (FPG) at five and eight years from baseline AEGIS data, c

101 sion were changes in fasting plasma glucose (FPG) between biopsies (per 10 mg/dL increase; odds ratio

102 as the difference in fasting plasma glucose (FPG) between the Control and Intervention arms after 6 w

103 empagliflozin on the fasting plasma glucose (FPG) concentration and beta-cell function in subjects wi

104 wered the diagnostic fasting plasma glucose (FPG) concentration from 7.8 to 7.0 mmol/L (140 to 126 mg

105 ently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) o

106 d the association of fasting plasma glucose (FPG) concentrations during pregnancy with offspring grow

107 by 14% and increased fasting plasma glucose (FPG) concentrations, fasting plasma insulin (FPI) concen

108 abetes diagnosis but fasting plasma glucose (FPG) has been useful for identifying patients with gluco

109 The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplan

110 preconception blood fasting plasma glucose (FPG) level and subsequent pregnancy outcomes.

111 6.5% or greater or a fasting plasma glucose (FPG) level of 126 mg/dL or greater (hemoglobin A1c or FP

112 2.5), and changes in fasting plasma glucose (FPG) levels and incidence of type 2 diabetes.

113 ionship between high fasting plasma glucose (FPG) levels and the risk of developing and dying for sev

114 sed on pre-pregnancy fasting plasma glucose (FPG) levels.

115 microbiota predicted fasting plasma glucose (FPG) longitudinally.

116 c)) and the level of fasting plasma glucose (FPG) maintained in pancreas transplant recipients?

117 uals with at least 2 fasting plasma glucose (FPG) measurements from January 1, 2005, to December 31,

118 l/mol) or greater or fasting plasma glucose (FPG) of 7.0 mmol/L or greater.

119 A fasting plasma glucose (FPG) test was used as the study outcome, signifying pote

120 Fasting plasma glucose (FPG) was measured from capillary blood using On-Call(R)

121 Gestational fasting plasma glucose (FPG) was positively associated with birth weight (B: 0.1

122 ion use, measures of fasting plasma glucose (FPG), 2 h plasma glucose, and HbA(1c).

123 iated with increased fasting plasma glucose (FPG), A1C, fasting insulin, and insulin resistance by ho

124 oglobin A1c (HbA1c), fasting plasma glucose (FPG), and 2-hour plasma glucose (2hPG).

125 al cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) on the risk of cardiovas

126 primary end point), fasting plasma glucose (FPG), and body weight were assessed at week 16.

127 s of FINDRISC score, fasting plasma glucose (FPG), and HbA1c.

128 iation with HbA(1c), fasting plasma glucose (FPG), and mean fasting plasma glucose (mFPG) measured ov

129 blood pressure (BP), fasting plasma glucose (FPG), and type 2 diabetes (T2D).

130 d by measurements of fasting plasma glucose (FPG), intravenous glucose disappearance rate (KG), HbA1c

131 c (primary outcome), fasting plasma glucose (FPG), serum N(euro)-(carboxymethyl) lysine (CML), and pe

132 tter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-w

133 oglobin A1c (HbA1c), fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), and hi

134 pressure (SBP), and fasting plasma glucose (FPG), triglyceride, and high-density lipoprotein (HDL)-c

135 dy mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cholesterol levels.

136 holesterol (TC), and fasting plasma glucose (FPG).

137 repeated measures of fasting plasma glucose (FPG).

138 ccording to donation fasting plasma glucose (FPG): <100 mg/dL (n = 6204), 100-125 mg/dL (n = 1826), a

139 Associations with fasting plasma glucose (FPG); 2 hr post-load glucose (2hG); area under the curve

140 ry outcomes included fasting plasma glucose (FPG); body weight; serum total, LDL, and HDL cholesterol

141 from NGT to abnormal fasting plasma glucose (FPG; > or =6.1 mmol/l), abnormal 2-h plasma glucose (2hP

142 inition of diabetes (fasting plasma glucose [FPG] > or = 126 mg/dl on two occasions, or a casual plas

143 sting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquartile [IQ] range 6.6-7.4),

144 = 56 +/- 2.2 years, fasting plasma glucose [FPG] = 8.4 +/- 1.3 mmol/L, HbA(1c) = 7.5 +/- 0.54%) with

145 moglycemia (baseline fasting plasma glucose [FPG] less than 100 mg/dL) from 6 United States of Americ

146 h adult BMI and high fasting plasma glucose [FPG], improved smoking, and improved drug use [encompass

147 NA with formamidopyrimidine DNA glycosylase (FPG) to convert 8-oxo-7,8-dihydroguanine (8-oxoGua) to a

148 G) and formamido-pyrimidine-DNA glycosylase (FPG), 3'-5' exonucleases, and enzymes with template-inde

149 se in formamidopyrimidine DNA N-glycosylase (FPG)-sensitive cleavage sites in mitochondrial DNA, comp

150 g the failure of fatty partial liver grafts (FPG) remain unknown.

151 axon 097 and Atopobium spp predicted greater FPG change, while Leptotrichia sp oral taxon 498 predict

152 abetes was defined as HbA1c 6.5% or greater, FPG 126 mg/dL or greater, or 2hPG 200 mg/dL or greater i

153 progression rates, a fast progression group (FPG) and slow progression group, as evidenced by differe

154 able analysis compared to a reference group (FPG < 84 mg/dL [< 4.7 mmol/L]).

155 ssified into three groups (normal FPG group: FPG < 5.6 mmol/L and no self-reported history of DM; imp

156 that significantly reduces levels of HbA1c, FPG, and CML, and improves periodontal therapy outcome i

157 Levels of HbA1c, FPG, body weight, TG, and SBP decreased linearly with th

158 adults with T2D, danuglipron reduced HbA1c, FPG, and body weight at week 16 compared with placebo, w

159 9]), drug use (8.4% [2.6 to 15.3]), and high FPG (6.2% [-2.7 to 15.6]; non-significant).

160 we found moderate relationships between high FPG and the risk of breast, pancreatic, and colorectal c

161 : 100-125 mg/dL [5.6-6.9 mmol/L]), and high (FPG >= 126 mg/dL [>= 7.0 mmol/L]).

162 For 1 mmol/L higher FPG, RRs in this age group were 1.18 (1.08-1.29) for IHD

163 h impaired FPG should, at minimum, have home FPG testing.

164 t patients are monitored for PTDM by 12-hour FPG levels drawn for clinic visits.

165 ciated with increased risk for diabetes (ie, FPG <70 mg/dL: HR, 3.49 [95% CI, 2.19-5.57]; FPG 120-125

166 and risk more than doubled again to 28.0% if FPG level also increased to 105 to 109 mg/dL.

167 lasma glucose (2hPG; > or =7.8 mmol/l), IFG (FPG 6.1-6.9 mmol/l, 2hPG < or =7.8 mmol/l), and IGT (FPG

168 <110 mg/dl), impaired fasting glucose (IFG, FPG 110-125 mg/dl), and type 2 diabetes (FPG >126 mg/dl)

169 story of DM; impaired fasting glucose [IFG]: FPG 5.6-6.9 mmol/L and no self-reported history of DM; a

170 6.9 mmol/l, 2hPG < or =7.8 mmol/l), and IGT (FPG <6.1 mmol/l, 2hPG 7.8-11.0 mmol/l), and from IFG-IGT

171 ollow-up; among subjects developing impaired FPG or 2hPG, 22% progressed to diabetes by FPG whereas 1

172 ll renal transplant recipients with impaired FPG should, at minimum, have home FPG testing.

173 incorporation was 25% in LPG but only 5% in FPG, and graft weight increased by 64% in LPG while rema

174 s associated with a 0.085 mmol/L increase in FPG ([95% confidence interval, CI=0.07-0.10], p=2.85x10(

175 ) was inversely related with the increase in FPG concentration (r=-36, r=0.001), whereas DeltaC-pep[A

176 g) was associated with stepwise increases in FPG and insulin and reduced hepatic insulin sensitivity.

177 o dideoxynucleoside analogs and increases in FPG are related with HS progression.

178 d NADH dehydrogenase-3 decreased markedly in FPG, and these effects were blocked by N-(1-naphtyl)ethy

179 rosine adducts) increased more profoundly in FPG than in lean partial grafts (LPG).

180 d by 64% in LPG while remaining unchanged in FPG.

181 All initial FPG levels outside a range of 80 to 94 mg/dL were associ

182 illary blood glucose [CapBG] >/=11.1 mmol/L, FPG >/=7.0 mmol/L, 2-hr plasma glucose >/=11.1 mmol/L, o

183 nce had significant difference for HDL, LDL, FPG, Fasting plasma insulin, and GGT.

184 totrichia sp oral taxon 498 predicted lesser FPG change (all 3 P values, Bonferroni significant).

185 Likewise, FPG and CML levels were significantly reduced in the pro

186 baseline subgingival plaque and longitudinal FPG were measured.

187 d into three glycemic level categories: low (FPG < 100 mg/dL [< 5.5 mmol/L]), moderate (FPG: 100-125

188 and a known bifunctional glycosylase/lyase (FPG), the results of which were used in comparison with

189 mprove any baseline metabolic parameters (M, FPG, FPI, HOMA-IR) in individuals with obesity and insul

190 ned free of insulin treatment and maintained FPG <126 mg/dl and HbA1c levels <6.5%.

191 Maternal FPG was significantly and positively associated with bre

192 At birth, maternal FPG during pregnancy was significantly associated with o

193 At 7 y, higher maternal FPG concentrations were significantly associated with in

194 with gestational diabetes mellitus, maternal FPG concentrations during pregnancy were significantly a

195 Mean FPG and diabetes prevalence in 2008 were also high in so

196 Mean FPG in 2008 was lowest in sub-Saharan Africa, east and s

197 Bayesian hierarchical model to estimate mean FPG and its uncertainty by age, country, and year, accou

198 a had the largest rise, and the highest mean FPG (6.09 mmol/L, 5.73-6.49 for men; 6.08 mmol/L, 5.72-6

199 We recorded almost no change in mean FPG in east and southeast Asia and central and eastern E

200 In 2008, global age-standardised mean FPG was 5.50 mmol/L (95% uncertainty interval 5.37-5.63)

201 (FPG < 100 mg/dL [< 5.5 mmol/L]), moderate (FPG: 100-125 mg/dL [5.6-6.9 mmol/L]), and high (FPG >= 1

202 and GDM risk factors interactions modulating FPG and GDM were observed.

203 st 2 FPG values, and those missing 6 or more FPG values.

204 ]); (3) diabetes diagnosed solely by the new FPG concentration criterion of 7.0 through 7.7 mmol/L (1

205 Among diabetic patients diagnosed by the new FPG criterion only, HbA1c levels were normal in 60.9% (5

206 glucose concentration (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting glucose (IFG, FPG 110-

207 en were classified into three groups (normal FPG group: FPG < 5.6 mmol/L and no self-reported history

208 Among subjects with normal FPG concentrations, HbA1c levels in the NHANES III (and

209 Compared with women with normal FPG, women with IFG had higher risks of spontaneous abor

210 ticipants were categorized as normoglycemic (FPG <5.6 mmol/L), prediabetic (FPG 5.6-6.9 mmol/L), or d

211 On the basis of FPG before treatment, participants were categorized as n

212 The median concentration of FPG-sensitive sites, measured with the comet assay, was

213 The detection of FPG- and endo III-sensitive DNA lesions revealed the pre

214 Modifications of the dietary effects of FPG and FI before treatment were examined with linear mi

215 lycosylation but with moderate elevations of FPG concentrations (6.1-7.7 mmol/L [110-139 mg/dL]) shou

216 e synthase (iNOS) plays a role in failure of FPG.

217 This study confirms the inadequacy of FPG screening for NODAT in the first 6 weeks after trans

218 The slope of increase of FPG with age over 10 years was also greater in Alzheimer

219 was associated with significant reduction of FPG and HbA1c at 26 weeks when compared to standard care

220 tervention led to a significant reduction of FPG at 26 weeks in the Intervention arm when compared to

221 The mean slope of FPG over 10 years in each case was also compared between

222 liver regeneration, and improved survival of FPG.

223 and 5.5-fold higher after transplantation of FPG than LPG.

224 suggested that the effect of the Q allele on FPG and HOMA-IR was stronger in those with a higher BMI

225 in NHES-Thailand, 16% (SE = 0.004), based on FPG (5.6 to < 7.0 mmol/L) and in HS-England, 19% (0.007)

226 oup was divided into four subgroups based on FPG levels.

227 =126 mg/dL, prediabetes as A1C 5.7%-<6.5% or FPG 100-<126 mg/dL, and normal glucose as A1C <5.7% and

228 total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8% (95% CI, 8.9%-10.6%)

229 l of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally including 2-hour pla

230 total diabetes (using the hemoglobin A1c or FPG definition) was 12.3% (95% CI, 10.8%-14.1%); among t

231 s diagnosed with diabetes using HbA1c and/or FPG diagnostic criteria.

232 diabetes (HbA1c 5.7-6.4% [39-46 mmol/mol] or FPG 5.6-6.9 mmol/L) at baseline.

233 Overnight FPG are inadequate for diagnosis of PTDM.

234 itive association of variables, particularly FPG level and BMI.

235 m 37.28% (337) had an elevated preconception FPG level (>= 5.6 mmol/L), regarded as noncontrolled DM.

236 Preconceptional FPG levels >= 100 mg/dL [>= 5.5 mmol/L] in women with pr

237 ormoglycemic (FPG <5.6 mmol/L), prediabetic (FPG 5.6-6.9 mmol/L), or diabetic (FPG >/=7.0 mmol/L).

238 Baseline levels of 9 taxa predicted FPG change (all FDR <0.05), among which Stomatobaculum s

239 ; and (4) diabetes diagnosed by the previous FPG concentration criterion of 7.8 mmol/L (140 mg/dL) or

240 All rats that received FPG died, whereas all those receiving LPG survived.

241 with SBP (r = 0.30 and 0.19, respectively), FPG (r = 0.25 and 0.22, respectively), triglycerides (r

242 with SBP (r = 0.22 and 0.22, respectively), FPG (r = 0.22 and 0.25, respectively), triglycerides (r

243 diposity are positively associated with SBP, FPG, and triglycerides and inversely associated with HDL

244 the preconception health examination, serum FPG concentration was measured, and self-reported histor

245 2 and the major allele of the rs1887922 SNP (FPG P < 0.001, mFPG P < 0.003, HbA(1c) P < 0.025).

246 gnoses were made based on prelunch or supper FPG >200 mg/dl.

247 We cross-tabulated FPG concentrations (<6.1 mmol/L [110 mg/dL], 6.1-6.9 mmo

248 e with GCK mutations as having diabetes than FPG >/=7 mmol/l (68% vs. 48%, p = 0.0009).

249 rt study of 44 992 individuals suggests that FPG level, age, BMI, and male sex were all associated wi

250 The FPG concentration decreased only in subjects with IFG fr

251 The FPG concentration remained unchanged (95 +/- 2 to 94 +/-

252 There was no significant difference in the FPG change between the Control and Intervention arms at

253 I has an intercalation motif observed in the FPG DNA glycosylase family of repair enzymes.

254 id not eliminate the severe phenotype in the FPG facial nucleus, suggesting that the FPG phenotype is

255 the FPG facial nucleus, suggesting that the FPG phenotype is the result of a more severe or accelera

256 isease-associated gene expression within the FPG facial motor nucleus confirmed the presence of a mor

257 ic control status was evaluated according to FPG value in women with DM.

258 as the main outcome, was based on follow-up FPG, review of hospital records, or self-reported physic

259 sed by self-report, diabetes medication use, FPG >or=126 mg/dl, and/or plasma glucose >or=200 mg/dl a

260 Clinic visit FPG levels did not differ between PTDM and non-PTDM pati

261 moglobin) that contained individuals in whom FPG concentrations, 2-hour glucose concentrations using

262 0.013), 4% with HbA1c (P<0.001), and 0% with FPG (P<0.001; n=26).

263 c versus 20% with OGTT (P=0.600) and 2% with FPG (P=0.059; n=50), whereas, at 12 months, NODAT was fo

264 A1c versus 6% with OGTT (P=1.00) and 2% with FPG (P=0.618; n=51).

265 aC-pep[AUC]15-120 positively correlated with FPG concentration (r=0.29, r<0.05).

266 ses of ESKD developed in the 250 donors with FPG >=126 mg/dL at 18.6 +/- 10.3 y after donation (aHR,

267 Donors with IFG and those with FPG >=126 mg/dL were older, less likely to be non-Hispan

268 r filtration rate were similar to those with FPG <126 mg/dL.

269 abetes should not be diagnosed in those with FPG concentrations less than 7.8 mmol/L (140 mg/dL) unle

270 The finding that women with FPG 110 to 125 mg/dl had similar CHD risk compared with

271 Women with FPG 5.1 mmol/L during pregnancy breastfeed for a shorter

272 Mean 2-y FPG change was 1.5 +/- 8 mg/dL.

273 ol subjects (n = 11, age = 54 +/- 1.8 years, FPG = 4.8 +/- 0.2 mmol/L) using resting-state functional